Debiopharm’s PR on the NVS deal for Debio 025 is essentially identical to NVS’ PR in #msg-46432280 (no financial details): http://finance.yahoo.com/news/Debiopharm-Group-Grants-an-prnews-1081222395.html?x=0&.v=101 p.s. Lausanne, Switzerland, where Debiopharm is based, is one of the most scenic places I’ve ever been.